Knowledge and Awareness of Emerging Cancer Therapies and their
Regulations among Budding Scientists in India: A Survey

Pinky      Sharma; Vikas      Jhawat; Jatinder      Singh; Rohit      Dutt

doi:10.2174/0115733947268695231116100736

Abstract

Background: Academic clinical research is considered the most important for cancer research because it frequently tests novel drug combinations, investigates rarer diseases, and lowers the risk for future commercial investments. However, due to the potential risks to the cancer patient, clinical research is governed by strict regulations. In high-income countries, comprehensive cancer centers (CCCs) have been established to align academic clinical cancer research with the regulatory framework. In comparison, academic clinical cancer research is considered ineffective in low-income countries.

Methods: A cross-sectional, online survey was conducted to evaluate the knowledge of Indian health science students regarding cutting-edge cancer therapeutics and their underlying regulatory requirements.

Results: The survey found that 163 out of the 265 respondents were aware of the challenges of developing safe and effective anticancer therapeutics. 43 respondents found no challenges, while 59 respondents were unaware of any. Out of 163, 44 respondents identified technical challenges, 31 identified regulatory issues, and 88 identified both challenges in developing novel anticancer therapeutics. Interestingly, only 83 students out of 265, study cancer therapy regulations in their curriculum. This clearly indicates that most of India's health science students have a significant lack of understanding about the regulations for new cancer treatments.

Conclusion: Academic clinical cancer research in India is just recognized as a prerequisite for degree completion due to a lack of regulatory foundation. An emphasis should be placed on restructuring the coursework offered to health science students to improve their ability to translate theoretical cancer research to real-world clinical care.

« Previous Next »

Graphical Abstract

[1]
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin  2022; 72(1): 7-33.
 [http://dx.doi.org/10.3322/caac.21708] [PMID:  35020204]

[2]
Cancer.  2022.https://www.who.int/news-room/fact-sheets/detail/cancer

[3]
Debela DT, Muzazu SGY, Heraro KD, et al. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med  2021; 9.
 [http://dx.doi.org/10.1177/20503121211034366] [PMID:  34408877]

[4]
Pucci C, Martinelli C, Ciofani G. Innovative approaches for cancer treatment: current perspectives and new challenges. Ecancermedicalscience  2019; 13: 961.
 [http://dx.doi.org/10.3332/ecancer.2019.961] [PMID:  31537986]

[5]
Xia P, Liu DH. Cancer stem cell markers for liver cancer and pancreatic cancer. Stem Cell Res  2022; 60: 102701.
 [http://dx.doi.org/10.1016/j.scr.2022.102701] [PMID:  35149457]

[6]
Yamasaki F. Adolescent and young adult brain tumors: current topics and review. Int J Clin Oncol  2022; 27(3): 457-64.
 [http://dx.doi.org/10.1007/s10147-021-02084-7] [PMID:  35064353]

[7]
Sundar SJ, Shakya S, Barnett A, et al. Three-dimensional organoid culture unveils resistance to clinical therapies in adult and pediatric glioblastoma. Transl Oncol  2022; 15(1): 101251.
 [http://dx.doi.org/10.1016/j.tranon.2021.101251] [PMID:  34700192]

[8]
Nie X, Shi C, Chen X, et al. A single-shot prophylactic tumor vaccine enabled by an injectable biomembrane hydrogel. Acta Biomater  2023; 169: 306-16.
 [http://dx.doi.org/10.1016/j.actbio.2023.08.010] [PMID:  37574158]

[9]
Chen X, Jiang Z, Lin Y, et al. Tumor lysates-constructed hydrogel to potentiate tumor immunotherapy. J Control Release  2023; 358: 345-57.
 [http://dx.doi.org/10.1016/j.jconrel.2023.05.005] [PMID:  37150404]

[10]
Ren X, Wang N, Zhou Y, et al. An injectable hydrogel using an immunomodulating gelator for amplified tumor immunotherapy by blocking the arginase pathway. Acta Biomater  2021; 124: 179-90.
 [http://dx.doi.org/10.1016/j.actbio.2021.01.041] [PMID:  33524560]

[11]
 2019. https://www.fda.gov/vaccines-blood-biologics/guidancecompliance-regulatory-information-biologics

[12]
Gogtay N, Ravi R, Thatte U. Regulatory requirements for clinical trials in India: What academicians need to know. Indian J Anaesth  2017; 61(3): 192-9.
 [http://dx.doi.org/10.4103/ija.IJA_143_17] [PMID:  28405032]

[13]
C. for DE and R. (CDER) ; US food and drug administration, C. for BE and R. (CBER) us food and drug administration, guidance for industry S9 nonclinical evaluation for anticancer pharmaceuticals 2018.https://www.fda.gov/media/100344/download

[14]
Schirrmacher V. From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review). Int J Oncol  2018; 54(2): 407-19.
 [http://dx.doi.org/10.3892/ijo.2018.4661] [PMID:  30570109 ]

[15]
Deli T, Orosz M, Jakab A. Hormone replacement therapy in cancer survivors – review of the literature. Pathol Oncol Res  2020; 26(1): 63-78.
 [http://dx.doi.org/10.1007/s12253-018-00569-x] [PMID:  30617760]

[16]
Silva RE, Amato AA, Guilhem DB, Novaes MRCG. Globalization of clinical trials: Ethical and regulatory implications. Int J Clin Trials  2016; 3(1): 1.
 [http://dx.doi.org/10.18203/2349-3259.ijct20160472]

[17]
Jeong S, Sohn M, Kim JH, et al. Current globalization of drug interventional clinical trials: Characteristics and associated factors, 2011–2013. Trials  2017; 18(1): 288.
 [http://dx.doi.org/10.1186/s13063-017-2025-1] [PMID:  28637515]

[18]
Riter RN, Weiss RS. Connecting Students with Patients and Survivors to Enhance Cancer Research Training Cancer Res  2019; 79: 4011-4.
 [http://dx.doi.org/10.1158/0008-5472.CAN-19-0603]

[19]
Seyhan AA. Lost in translation: The valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles. Transl Med Commun  2019; 4(1): 18.
 [http://dx.doi.org/10.1186/s41231-019-0050-7]

[20]
Bérubé G. How to utilize academic research efforts in cancer drug discovery. Expert Opin Drug Discov  2019; 14(4): 331-4.
 [http://dx.doi.org/10.1080/17460441.2019.1582637] [PMID:  30784328]

[21]
European Society for Medical Oncology, CAREFOR, The Clinical Academic Cancer Research Forum 2020.  Available From: https://www.esmo.org/policy/carefor-the-clinical-academic-cancer-research-forum

[22]
Cagan R, Meyer P. Rethinking cancer: Current challenges and opportunities in cancer research. Dis Model Mech  2017; 10(4): 349-52.
 [http://dx.doi.org/10.1242/dmm.030007] [PMID:  28381596]

[23]
Hilal T, Gonzalez-Velez M, Prasad V. Limitations in clinical trials leading to anticancer drug approvals by the us food and drug administration. JAMA Intern Med  2020; 180(8): 1108-15.
 [http://dx.doi.org/10.1001/jamainternmed.2020.2250] [PMID:  32539071]

[24]
An American Society of Clinical Oncology and Institute of Medicine Workshop; Institute of Medicine; National Cancer Policy Forum; Board on Health Care Services., REGULATORY ISSUES, in: Implement. a Natl Cancer Clin Trials Syst 2013.http://www.nap.edu/

[25]
C for BE and R. (CBER); OC for E. US Food and Drug Administration, Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics Guidance for Industry  2018. https://www.fda.gov/media/71195/download

[26]
Guideline on the clinical evaluation of anticancer medicinal products  2019.

[27]
C. for drug evaluation and research; US food and drug administration, C. for BE and R. US food and drug administration placebos and blinding in randomized controlled cancer clinical trials for drug and biological products guidance for industry  2019.https://www.fda.gov/media/130326/download

[28]
Caldwell KJ, Gottschalk S, Talleur AC. Allogeneic CAR cell therapy-more than a pipe dream. Front Immunol  2021; 11: 618427.
 [http://dx.doi.org/10.3389/fimmu.2020.618427] [PMID:  33488631]

[29]
Karantalis V, Schulman IH, Balkan W, Hare JM. Allogeneic cell therapy: A new paradigm in therapeutics. Circ Res  2015; 116(1): 12-5.
 [http://dx.doi.org/10.1161/CIRCRESAHA.114.305495] [PMID:  25552688]

[30]
Cecilio-Fernandes D, Aalders WS, de Vries J, Tio RA. The impact of massed and spaced-out curriculum in oncology knowledge acquisition. J Cancer Educ  2018; 33(4): 922-5.
 [http://dx.doi.org/10.1007/s13187-017-1190-y] [PMID:  28194581]

[31]
Syllabus for MPharm Course Pharm Counc 2014. Available From: 
          https://www.pci.nic.in/pdf/Syllabus_M_Pharm.pdf (accessed April 16, 2023).

[32]
Syllabus for MPharm Course Pharm Counc 2014. Available From:
          https://www.pci.nic.in/pdf/Syllabus_B_Pharm.pdf (accessed April 16, 2023).

[33]
Syllabus MBBS at the AIIMS All India Inst Med Sci New Delhi - 110 029 2005. Available From: 
          https://www.aiims.edu/aiims/academic/aiims-syllabus/Syllabus-M BBS.pdf (accessed April 16, 2023).

[34]
Ranganathan P, Gadgil D, Sengar M, Pramesh CS, Badwe R. Building research capacity in India: The masters in clinical research program at the tata memorial centre. Perspect Clin Res  2021; 12(4): 189-92.
 [http://dx.doi.org/10.4103/picr.picr_48_21] [PMID:  34760645]

[35]
Oberst S. Bridging research and clinical care – the comprehensive cancer centre. Mol Oncol  2019; 13(3): 614-8.
 [http://dx.doi.org/10.1002/1878-0261.12442] [PMID:  30628155]

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0115733947268695231116100736	Print ISSN 1573-3947
Publisher Name Bentham Science Publisher	Online ISSN 1875-6301

Current Cancer Therapy Reviews

Knowledge and Awareness of Emerging Cancer Therapies and their Regulations among Budding Scientists in India: A Survey

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Abstract